J Cancer 2014; 5(8):628-632. doi:10.7150/jca.9409 This issue Cite

Research Paper

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas

Ingrid Holst Olsen1,2,4,5,6✉, Ulrich Knigge2,5,6, Birgitte Federspiel3,6, Carsten Palnæs Hansen2,6, Anna Skov2, Andreas Kjær4,5,6, Seppo W. Langer1,6

1. Depts of Oncology 5073, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark;
2. Depts of Surgery 2122, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark;
3. Depts of Pathology 5442, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark;
4. Depts of Clinical Physiology, Nuclear Medicine & PET 4011, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark;
5. Cluster of Molecular Imaging, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark;
6. European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark.

Citation:
Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW. Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. J Cancer 2014; 5(8):628-632. doi:10.7150/jca.9409. https://www.jcancer.org/v05p0628.htm
Other styles

File import instruction

Abstract

Background: Neuroendocrine carcinomas (WHO grade 3) are highly aggressive tumors with an immense tendency to metastasize and with a poor prognosis. In advanced disease, there is no standard treatment beyond first-line platin/etoposide-based chemotherapy. Topotecan is widely used as second-line treatment in small cell lung cancer, which also responds markedly on first-line platin/etoposide. Hence, we investigated the feasibility of topotecan in previously treated patients with neuroendocrine carcinomas.

Material and Methods: Retrospective analysis of 22 patients with disseminated and progressive neuroendocrine carcinomas (Ki67>20%, G3) successively treated with oral topotecan 2.3 mg/m2 d1-5 every 3 weeks. All patients had previously received treatment with carboplatin/etoposide. Demographic, clinical and pathological features were recorded. CT-evaluations according to RECIST 1.1 were performed after every three courses. Hematological toxicity was assessed by CTC-criteria.

Results: Twenty-two eligible patients received a median of 2 courses [range1-6]. Median age: 65 years [35-77]. Male/female: 11/11. Median Ki-67 index: 95% [25-100%]. Median number previous chemotherapy regimens: 2 [1-3]. All patients were evaluable for response: Five achieved stable disease (SD) and 17 progressed (PD). The median overall survival for the 22 patients was 3.2 months and the median progression-free survival was 2.1 months. The one-year survival was 18%. There were no treatment related deaths. The treatment was well tolerated: Haematological toxicity comprised leukopenia CTC grade 3 (14%), grade 4 (9%) and thrombocytopenia grade 3 (14%).

Conclusion: Topotecan monotherapy shows modest anti-tumor activity in heavily treated patients with progressive disseminated G3 neuroendocrine carcinomas.

Keywords: neuroendocrine carcinomas, chemotherapy, topotecan.


Citation styles

APA
Olsen, I.H., Knigge, U., Federspiel, B., Hansen, C.P., Skov, A., Kjær, A., Langer, S.W. (2014). Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. Journal of Cancer, 5(8), 628-632. https://doi.org/10.7150/jca.9409.

ACS
Olsen, I.H.; Knigge, U.; Federspiel, B.; Hansen, C.P.; Skov, A.; Kjær, A.; Langer, S.W. Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. J. Cancer 2014, 5 (8), 628-632. DOI: 10.7150/jca.9409.

NLM
Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW. Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. J Cancer 2014; 5(8):628-632. doi:10.7150/jca.9409. https://www.jcancer.org/v05p0628.htm

CSE
Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW. 2014. Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. J Cancer. 5(8):628-632.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image